Roth Capital affirms its Buy rating and $33 price target on TG Therapeutics (Nasdaq: TGTX) following news that the company entered a collaboration agreement with Checkpoint Therapeutics, a new subsidiary of Coronado (Nasdaq: CNDO), in which both companies will develop two fully human antibodies, anti-PD-L1 and anti-GITR.
Analyst Joseph Pantginis said, This agreement marks TGTX's entry into the immuno-oncology space and can potentially further increase its visibility once assets are in the clinic. This pipeline expansion signals continued BD efforts at TGTX with previous in-licensing of the IRAK4 inhibitor from Ligand (LGND-Buy) and its ongoing combo studies with Pharmacyclics' (PCYC-Neutral) Imbruvica. These two new programs also present an opportunity to initiate combination studies with '1101 and '1202, similar to ongoing combination studies with Imbruvica, which have been very promising to date. The Phase III GENUINE study of '1101 + Imbruvica in high risk CLL patients is listed on clinicaltrials.gov as recruiting patients.
Recall that this randomized study will enroll ~330 patients and compare TG-1101 +/- Imbruvica. The primary endpoint of the study, as per the SPA will be overall response rate (ORR) which be analyzed following ~two-thirds of patients receiving treatment. All patients enrolled into the study will then be followed for progression free survival (PFS), which, should serve as the basis for full approval. TGTX is facing a busy year with regards to study initiations (two additional Phase III studies, triple therapy study, study in autoimmune diseases, IRAK4 study initiation) as well with regards to data releases (presentations expected at ASCO, EHA and ASH).
May 5th Equities researchers at Brean Capital set a $22.00 price target on shares of TG Therapeutics (NASDAQ:TGTX) stock in a research report issued on Tuesday. The firm currently has a a “buy” rating on the stock. Brean Capital’s target price would suggest a potential upside of 63.81% from the stock’s previous close. Several other analysts have also recently commented on the stock. Analysts at Roth Capital set a $33.00 price target on shares of TG Therapeutics and gave the company a “buy” rating in a research note on Monday, April 20th. Separately, analysts at MLV & Co. reiterated a “buy” rating and set a $22.00 price target on shares of TG Therapeutics in a research note on Sunday, March 15th. TG Therapeutics (NASDAQ:TGTX) traded down 6.35% on Tuesday, hitting $13.43. 1,073,818 shares of the company’s stock traded hands. TG Therapeutics has a one year low of $4.42 and a one year high of $20.00. The stock’s 50-day moving average is $16. and its 200-day moving average is $14.. The company’s market cap is $603.44 million. TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.06. The company had revenue of $38.10 million for the quarter. Analysts expect that TG Therapeutics will post $-1.43 EPS for the current fiscal year.
TG Therapeutics' TG-1101 + Imbruvica shows 95% response rate in high risk leukemia in updated results from mid-stage trial Jun 18 2015, 12:17 ET | About: TG Therapeutics, Inc. (TGTX) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip Updated data from a Phase 2 study evaluating TG Therapeutics' (TGTX +17.6%) investigational TG-1101 (ublituximab) in combination with ibrutinib (Pharmacyclics' (NYSE:ABBV) Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) showed a 95% overall response rate (n=19/20) with 20% (n=4/20) achieving MRD (minimal residual disease) negativity in CLL patients considered high risk. The data were presented at the 13th International Congress on Malignant Lymphoma in Lugano, Switzerland.In 40 evaluable patients, 88% (n=35/40) achieved an objective response and 10% (n=4/40) achieved nodal reductions of 20 - 55% without disease progression.The combination of TG-1101 and ibrutinib was well tolerated in the 44 patients treated. The most common Grade 3 or 4 (severe/life threatening) adverse events observed were neutropenia (11%) (n=5/44), anemia (11%) (n=5/44) and infusion-related reactions (7%) (n=3/44).A Phase 3 study, called GENUINE, comparing the combination of TG-1101 and ibrutinib to ibrutinib alone in previously-treated high risk CLL patients is underway. Total enrollment will be ~330. Results will support a Biologics License Application (BLA) for accelerated approval of TG-1101. The study's completion date is projected to be August 2018.
Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $33 price target on TG Therapeutics (NASDAQ: TGTX) after they received updated data from the Phase II TG-1101/Imbruvica combination study in CLL patients.
"The high-risk group showed a 95% response rate, compared to the 60-65% expectation for Imbruvica alone." Pantginis notes. "This high-risk group also represents the targeted patient in the ongoing Phase III GENUINE study and we believe these Phase II data continue to act as a strong proxy for a successful outcome of GENUINE."
Under: Been on the sidelines for a bit holding (building) cash. Now that "BIGLEY" has rolled out the tax plan its time to jump in.
Dec 21, 2017 19:06:02 GMT -6
martyc: Looks like you are buying Msft again!
Dec 15, 2017 11:23:29 GMT -6
martyc: The news that Trump called Rupert to congratulate him sure seems to indicate that this is heading to approval
Dec 15, 2017 11:22:23 GMT -6
Under: DIS finally getting some traction.?
Dec 14, 2017 17:08:45 GMT -6
martyc: I took an entry level position in DIS. Will add eventually to overweight when it becomes clearer that the deal will go thru. Can't believe how well positioned they will be. 60% Hulu. 20% of content watched on NFLX they can pull. More in thread
Dec 14, 2017 11:05:16 GMT -6
Under: Great posts on $DIS
Dec 13, 2017 17:50:49 GMT -6
Under: $ROKU Citron on a war path.
Nov 28, 2017 15:11:20 GMT -6
Under: $HAS takeover bid for $MAT?
Nov 10, 2017 16:16:07 GMT -6
martyc: Not looking like the market will provide any discounted opp for SGMO. Call was just too professional and all signs indicate they are on a great path for commercialization. Happy with core but wish I had some trading shs
Nov 10, 2017 9:04:05 GMT -6
martyc: For anyone looking to find an entry point into SGMO, I'm almost hoping is sells off in next few days so I can add more. They are really clicking but the fact they haven't signed new deals might cause some to exit. Watching as I have room for trading shs
Nov 9, 2017 18:28:09 GMT -6
martyc: Been an interesting ride so far. I figured the Bears would be about this good but hoped the O wouldn't look so lame. Another building yr but still possible to get to 8-8 IMO
Nov 9, 2017 18:26:08 GMT -6
Under: whats up with your Bears this year Marty?
Nov 9, 2017 17:35:25 GMT -6
martyc: Hope you were long ROKU. I wanted to see Q first so missed out
Nov 9, 2017 7:08:53 GMT -6